Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

NCT00756509 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals